Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis

Abstract Objectives: To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis. Methods: Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients’ charts. Results: A hypersensitivity reaction was observed in 12% of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75%, 13%, and 13% of the patients with hypersensitivity reaction, respectively, and in 28%, 42%, and 30% of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01). Conclusions: The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.

[1]  J. Gómez-Reino,et al.  Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases , 2013, Arthritis care & research.

[2]  M. Dougados,et al.  Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab , 2012, Annals of the rheumatic diseases.

[3]  S. Bombardieri,et al.  Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  H. Yamanaka,et al.  Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients , 2012, Modern rheumatology.

[5]  M. Benucci,et al.  Spondylarthritis presenting with an allergic immediate systemic reaction to adalimumab in a woman: a case report , 2011, Journal of medical case reports.

[6]  T. Takeuchi,et al.  Extended Report , 2022 .

[7]  W. Pichler.  Adverse side‐effects to biological agents , 2006, Allergy.

[8]  S. Luo,et al.  Association of rheumatoid factor production with FcγRIIIa polymorphism in Taiwanese rheumatoid arthritis , 2006, Clinical and experimental immunology.

[9]  J. Barrett,et al.  Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B , 2005, Arthritis research & therapy.

[10]  H. Harbo,et al.  Ethnic variation of Fcγ receptor polymorphism in Sami and Norwegian populations , 2005 .

[11]  J. S. Lee,et al.  The association between FcgRIIIB polymorphisms and systemic lupus erythematosus in Korea , 2005, Lupus.

[12]  M. Zago,et al.  Variation in the FcgammaR3B gene among distinct Brazilian populations. , 2005, Tissue antigens.

[13]  H. Harbo,et al.  Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. , 2005, Immunology.

[14]  T. Takai.  Roles of Fc receptors in autoimmunity , 2002, Nature Reviews Immunology.

[15]  C. Kallenberg,et al.  Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. , 2002, Arthritis and rheumatism.

[16]  C. Vedeler,et al.  Fcγ receptor polymorphisms in populations in Ethiopia and Norway , 2001 .

[17]  C. Vedeler,et al.  Fcgamma receptor polymorphisms in populations in Ethiopia and Norway. , 2001, Immunology.

[18]  M. Wilson,et al.  Evaluation of Human FcγRIIA (CD32) and FcγRIIIB (CD16) Polymorphisms in Caucasians and African-Americans Using Salivary DNA , 2000, Clinical Diagnostic Laboratory Immunology.